Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oncology

Biology & Pathology: Subtypes and Your Biopsy Report

At a Glance

Your PTLD pathology report is a crucial blueprint for your treatment. An excisional biopsy is the gold standard for accurately identifying the four WHO subtypes of PTLD. Key details like EBER testing for Epstein-Barr Virus and cell lineage will dictate your specific treatment options.

The pathology report is the most critical document in your PTLD journey. It is the “blueprint” that tells your medical team exactly what they are fighting. Understanding the terms within it—from the way the tissue was collected to the specific biological subtype—empowers you to ask the right questions about your care [1][2].

The Biopsy: Why Method Matters

When a doctor suspects PTLD, they need more than just a few cells; they need a look at the “neighborhood” (the architecture) where those cells live [3][4].

  • Excisional Biopsy (The Gold Standard): This involves removing a whole lymph node or a significant piece of tissue. It allows the pathologist to see if the normal structure of the organ is still there or if it has been “destroyed” by the overgrowth of cells [3][5].
  • Fine Needle Aspiration (FNA) (Usually Insufficient): An FNA uses a very thin needle to pull out a small sample of cells. While it is fast and less invasive, it usually doesn’t provide enough information to tell the difference between the complex subtypes of PTLD [4][6]. Without seeing the tissue architecture, a doctor might miss a more aggressive subtype hiding among less serious cells [4].

The Four WHO Subtypes

The World Health Organization (WHO) classifies PTLD into four main categories based on how the cells look and how they behave [7][8].

1. Non-destructive PTLD (Early Lesions)

These are the mildest forms. The normal structure of the lymph node is mostly preserved [7]. The cells are polyclonal, meaning they are a diverse mix of normal immune cells rather than a single “army” of clones [9].

  • Management: Often responds well to simply reducing immunosuppression drugs [10].

2. Polymorphic PTLD

In this subtype, the cells look “polymorphic” (many-shaped) [7]. You will see a mix of small and large immune cells. Unlike the monomorphic type, these don’t quite meet the full criteria for a specific cancer, but they are more aggressive than early lesions [9].

  • Management: May require a combination of reduced immunosuppression and targeted therapy like Rituximab [2].

3. Monomorphic PTLD (The Most Aggressive)

This is essentially a lymphoma that occurs after a transplant [7]. The cells are monomorphic (all one shape), meaning a single abnormal cell has “cloned” itself into a uniform sheet [9][11].

  • Key Fact: This subtype usually carries the poorest prognosis and lowest survival rates if not treated aggressively [10][12].
  • Management: Often requires standard chemotherapy in addition to other PTLD treatments because it behaves like a mature cancer [10][2].

4. Classic Hodgkin Lymphoma-type PTLD

This is the rarest form. It contains very specific cells called Reed-Sternberg cells [7][9]. It is treated similarly to how doctors treat Hodgkin lymphoma in people who haven’t had a transplant [2].

The EBER Test: The “Gold Standard”

Your report should mention a test called EBER In Situ Hybridization (ISH) [13].

  • What it is: A specialized lab test that looks for tiny pieces of Epstein-Barr Virus (EBV) genetic material (RNA) inside the actual cells [13][14].
  • Why it’s important: It is the most accurate way to prove that EBV is driving the growth of those specific cells [13]. Knowing if a lesion is “EBER-positive” or “EBER-negative” is essential because some new treatments (like T-cell therapies) only work if the virus is present [15][16].

Completeness Checklist for Your Report

Check your pathology report for these specific items. If any are missing, ask your doctor why.

  • [ ] Sample Type: Was it an excisional biopsy, core biopsy, or FNA? [3]
  • [ ] WHO Subtype: Is it explicitly listed (e.g., “Polymorphic PTLD”)? [1]
  • [ ] EBER Status: Is it listed as EBER-positive or EBER-negative? [17]
  • [ ] Lineage: Are the cells B-cells or T-cells? [1]
  • [ ] Specific Lymphoma Match: For monomorphic types, does it name a counterpart (e.g., “DLBCL”)? [2]
  • [ ] Molecular Markers: For aggressive cases, were MYC or BCL2 rearrangements checked? [18]

Common questions in this guide

What is the difference between an excisional biopsy and an FNA for PTLD?
An excisional biopsy removes a whole lymph node or a large piece of tissue, allowing the pathologist to see the tissue's structure. A fine needle aspiration (FNA) only removes a few cells and usually does not provide enough information to identify the complex subtypes of PTLD.
What does an EBER-positive result mean on my pathology report?
An EBER-positive result means that genetic material from the Epstein-Barr Virus (EBV) was found inside the abnormal cells. This confirms that EBV is driving the cell growth and can help determine if specific targeted therapies will be effective for your treatment.
What is monomorphic PTLD?
Monomorphic PTLD is the most aggressive subtype where a single abnormal cell has cloned itself into a uniform sheet, behaving much like a mature cancer. It typically requires intensive treatments, such as standard chemotherapy, in addition to other PTLD therapies.
Why is it important to know my specific WHO subtype for PTLD?
The World Health Organization (WHO) categorizes PTLD into four main subtypes that range from early, mild lesions to aggressive cancers. Knowing your exact subtype is crucial because it directly dictates whether you need simple medication adjustments or intensive treatments like chemotherapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does the biopsy report explicitly state my EBER status, and what does it mean for my treatment?
  2. 2.Why was an excisional biopsy (or core biopsy) performed instead of an FNA, and are you confident it captured the full picture of the tissue architecture?
  3. 3.My report says 'Monomorphic PTLD.' Which specific lymphoma subtype does it resemble (e.g., DLBCL or Burkitt), and how does that change the aggressiveness of my treatment plan?
  4. 4.Were tests for 'cell-of-origin' markers or molecular rearrangements (like MYC or BCL2) performed?
  5. 5.Based on this subtype, what is the current goal of my therapy: reduction of immunosuppression alone, or do we need to start chemotherapy/Rituximab immediately?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    New developments in non-Hodgkin lymphoid malignancies.

    Ganapathi KA, Brown LE, Prakash S, Bhargava P

    Pathology 2021; (53(3)):349-366 doi:10.1016/j.pathol.2021.01.002.

    PMID: 33685720
  2. 2

    Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

    Allen UD, Preiksaitis JK,

    Clinical transplantation 2019; (33(9)):e13652 doi:10.1111/ctr.13652.

    PMID: 31230381
  3. 3

    Evaluation of peripheral lymphadenopathy with excisional biopsy: six-year experience.

    Özkan EA, Göret CC, Özdemir ZT, et al.

    International journal of clinical and experimental pathology 2015; (8(11)):15234-9.

    PMID: 26823872
  4. 4

    Diagnostic value of lymph node fine-needle aspiration cytology.

    Ton Eryilmaz O, Ucak R, Ozagari AA, Kabukcuoglu F

    CytoJournal 2021; (18()):8 doi:10.25259/Cytojournal_1_2020.

    PMID: 34221097
  5. 5

    Letter to the Editor: Fine-needle aspiration cytology and core-needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement.

    Al-Abbadi M, Barroca H, Bode-Lesniewska B, et al.

    European journal of haematology 2021; (107(2)):295-296 doi:10.1111/ejh.13646.

    PMID: 33961309
  6. 6

    Cytological Diagnosis of Aggressive Small-Cell Lymphomas.

    Caputo A, Ciliberti V, Zeppa P, D'Antonio A

    Acta cytologica 2022; (66(4)):269-278 doi:10.1159/000524270.

    PMID: 35385847
  7. 7

    Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: Diagnostic overlaps and defining features.

    Volaric AK, Fedoriw Y

    Human pathology 2025; (156()):105697 doi:10.1016/j.humpath.2024.105697.

    PMID: 39571693
  8. 8

    Post-transplant lymphoproliferative disorder with cutaneous involvement: A series of four cases.

    Ferreira MCC, Arai Seque C, Enokihara MMSES, et al.

    Clinical transplantation 2021; (35(2)):e14162 doi:10.1111/ctr.14162.

    PMID: 33217057
  9. 9

    Pediatric post-transplant lymphoproliferative disorder: Do not overlook digestive involvement.

    Le Calvez B, Samarji B, Hubert G, et al.

    Pediatric blood & cancer 2023; e30353 doi:10.1002/pbc.30353.

    PMID: 37073610
  10. 10

    Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients.

    Liu Y, Wang BC, Zuppan CW, et al.

    Cancers 2023; (15(3)) doi:10.3390/cancers15030976.

    PMID: 36765933
  11. 11

    Diverse clinical and histopathologic features of cutaneous post-transplant lymphoproliferative disorders: A presentation of two cases.

    Roberts SJ, McNally B, Rosser JA, et al.

    The Australasian journal of dermatology 2019; (60(4)):e317-e321 doi:10.1111/ajd.13076.

    PMID: 31144292
  12. 12

    Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [18F]FDG PET/CT.

    Montes de Jesus F, Vergote V, Noordzij W, et al.

    Journal of clinical medicine 2021; (10(2)) doi:10.3390/jcm10020361.

    PMID: 33477971
  13. 13

    Detection of Epstein-Barr virus encoded RNA in fixed cells and tissues using CRISPR/Cas-mediated RCasFISH.

    Chen K, Wang M, Zhang R, Li J

    Analytical biochemistry 2021; (625()):114211 doi:10.1016/j.ab.2021.114211.

    PMID: 33915117
  14. 14

    Quantitative PCR for Plasma Epstein-Barr Virus Loads in Cancer Diagnostics.

    Loghavi S

    Methods in molecular biology (Clifton, N.J.) 2016; (1392()):51-61 doi:10.1007/978-1-4939-3360-0_6.

    PMID: 26843046
  15. 15

    Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.

    Mahadeo KM, Baiocchi R, Beitinjaneh A, et al.

    The Lancet. Oncology 2024; (25(3)):376-387 doi:10.1016/S1470-2045(23)00649-6.

    PMID: 38309282
  16. 16

    Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.

    Barlev A, Zimmermann H, Guzman-Becerra N, et al.

    Journal of medical economics 2024; (27(1)):789-795 doi:10.1080/13696998.2024.2354150.

    PMID: 38727527
  17. 17

    Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.

    Chen DB, Liu XY, Kong FZ, et al.

    Journal of clinical pathology 2021; (74(11)):697-703 doi:10.1136/jclinpath-2021-207492.

    PMID: 34011618
  18. 18

    Primary central nervous system post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation: a case report.

    Tugend M, Dattero J, Shore T, et al.

    Frontiers in oncology 2024; (14()):1284577 doi:10.3389/fonc.2024.1284577.

    PMID: 38313803

This page explains PTLD pathology terminology for educational purposes only. Always consult your pathologist or transplant oncologist to interpret your specific biopsy results and determine your treatment plan.

Get notified when new evidence is published on Post-transplant lymphoproliferative disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.